RJFSA
CDTX

Raymond James Financial Services Advisors’s Cidara Therapeutics CDTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,878
Closed -$71.3K – 3424
2024
Q1 		$71.3K Sell
3,878
-65
-2% -$933 ﹤0.01% 3263
2023
Q4 		$62.6K Sell
3,943
-13
-0.3% -$209 ﹤0.01% 3178
2023
Q3 		$74.5K Buy
3,956
+796
+25% +$15.6K ﹤0.01% 3112
2023
Q2 		$71.4K Sell
3,160
-323
-9% -$7.59K ﹤0.01% 3103
2023
Q1 		$88.5K Sell
3,483
-200
-5% -$5.67K ﹤0.01% 3063
2022
Q4 		$55.7K Sell
3,683
-751
-17% -$8.96K ﹤0.01% 3078
2022
Q3 		$56K Buy
4,434
+97
+2% +$1.34K ﹤0.01% 3074
2022
Q2 		$42K Buy
4,337
+23
+0.5% +$284 ﹤0.01% 3101
2022
Q1 		$72K Buy
4,314
+562
+15% +$9.53K ﹤0.01% 3151
2021
Q4 		$95K Sell
3,752
-715
-16% -$22.3K ﹤0.01% 3128
2021
Q3 		$200K Sell
4,467
-250
-5% -$9.5K ﹤0.01% 2982
2021
Q2 		$191K Buy
4,717
+382
+9% +$16.2K ﹤0.01% 3024
2021
Q1 		$231K Sell
4,335
-139
-3% -$6.86K ﹤0.01% 2816
2020
Q4 		$179K Sell
4,474
-430
-9% -$21.4K ﹤0.01% 2752
2020
Q3 		$280K Sell
4,904
-197
-4% -$13.9K ﹤0.01% 2317
2020
Q2 		$376K Buy
+5,101
New +$331K ﹤0.01% 2099
2020
Q1 		– Sell
-6,211
Closed -$477K – 2461
2019
Q4 		$477K Buy
6,211
+1,079
+21% +$49.4K ﹤0.01% 2012
2019
Q3 		$205K Sell
5,132
-1,244
-20% -$41.8K ﹤0.01% 2491
2019
Q2 		$214K Sell
6,376
-885
-12% -$36.8K ﹤0.01% 2493
2019
Q1 		$385K Sell
7,261
-6,233
-46% -$342K ﹤0.01% 2055
2018
Q4 		$634K Buy
13,494
+2,866
+27% +$205K ﹤0.01% 1520
2018
Q3 		$935K Buy
10,628
+2,197
+26% +$194K ﹤0.01% 1501
2018
Q2 		$877K Buy
8,431
+4,981
+144% +$470K ﹤0.01% 1504
2018
Q1 		$276K Buy
3,450
+1,961
+132% +$268K ﹤0.01% 2079
2017
Q4 		$203K Buy
1,489
+290
+24% +$44K ﹤0.01% 2260
2017
Q3 		$194K Buy
1,199
+325
+37% +$46.2K ﹤0.01% 2286
2017
Q2 		$131K Buy
+874
New +$121K ﹤0.01% 2309

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Raymond James Financial Services Advisors's CDTX Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 3,878 shares — an estimated $71.3K sold.

Raymond James Financial Services Advisors first reported a position in CDTX in Q2 2017 and held it in 27 quarters. The position peaked at $935K in Q3 2018. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 3,878 Cidara Therapeutics shares in Q2 2024, an estimated $71.3K.
  • Raymond James Financial Services Advisors first reported a position in Cidara Therapeutics in Q2 2017 and held it in 27 quarters.
  • Raymond James Financial Services Advisors's Cidara Therapeutics position peaked at $935K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.